Compare W W Grainger Inc (GWW) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? W W Grainger Inc trades at $1,330.68 (market cap $62.67B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: W W Grainger Inc is far larger — about 64.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and W W Grainger Inc pays a 0.75% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 26 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GWW | MRVI | |
|---|---|---|
Market Cap | $62.67B | $977.37M |
Volume | 440,928 | 2,742,564 |
Sector | Industrials | Health |
52-Week High | $1.40K | $9.00 |
52-Week Low | $918.18 | $2.83 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $64.88B | $1.08B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,325.10, up 1.41% today, with a bullish technical signal and strong fundamentals including a 47.92% ROE and 9.92% net income margin. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a solid dividend as a Dividend King. Institutional buying and positive analyst coverage support the stock's momentum.
Outlook remains positive with a consensus price target of $1,310, though high valuation multiples and competitive pressures pose risks. Earnings growth and market share gains in industrial distribution are key drivers for continued upside.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
